INDUSTRY UPDATE

ADHD Telehealth in Australia 2026: How GPs Can Now Prescribe Stimulants

Published 1 May 2026 · 12 min read · Updated regularly

For years, Australians with suspected ADHD faced a brutal bottleneck: the only pathway to diagnosis and treatment was through a psychiatrist, and waitlists had blown out to 12–24 months in most capital cities, with rural and regional patients often waiting even longer. According to the Royal Australian College of General Practitioners (RACGP), the demand for ADHD assessment has surged dramatically since 2020, driven by increased awareness, reduced stigma, and a growing evidence base for the benefits of treatment in adults.

That bottleneck started cracking in late 2025, and by mid-2026, the landscape of ADHD care in Australia looks fundamentally different. Here's a comprehensive look at what changed, what it means for patients and GPs, and how specialist telehealth is reshaping access to ADHD treatment across the country.

The Problem: Why ADHD Care Was Broken

Australia's approach to ADHD treatment has historically been among the most restrictive in the developed world. Unlike the United Kingdom — where the National Institute for Health and Care Excellence (NICE) guidelines allow GPs to manage ongoing ADHD treatment — Australian regulations limited stimulant prescribing to psychiatrists and paediatricians in most states.

The consequences were predictable and well-documented. The Australian Institute of Health and Welfare (AIHW) reported that ADHD prevalence in Australian adults sits at approximately 2–5% of the population — meaning somewhere between 500,000 and 1.25 million adults may have ADHD. Yet Australia has roughly 4,000 practising psychiatrists serving a population of 26 million, and only a fraction of those specialise in adult ADHD. The maths simply never worked.

The result: patients falling through the cracks, turning to unregulated overseas pharmacies, self-medicating with caffeine and other substances, or simply going undiagnosed and untreated despite significant impairment in work, relationships, and daily functioning.

What Changed in Queensland (December 2025)

In December 2025, Queensland Health updated its regulatory framework to allow FRACGP-qualified general practitioners to assess, diagnose, and prescribe Schedule 8 stimulant medications for adult ADHD. This was a watershed moment — the first time any Australian state had meaningfully expanded GP prescribing authority for ADHD stimulants.

The key requirements under the Queensland framework:

GPs must hold FRACGP (Fellowship of the Royal Australian College of General Practitioners) or equivalent vocational fellowship. They must operate within appropriate clinical governance structures with access to peer support. They must follow evidence-based assessment protocols consistent with DSM-5 diagnostic criteria. And they must maintain appropriate documentation including validated screening tools such as the Adult ADHD Self-Report Scale (ASRS) and the Wender Utah Rating Scale.

The intent behind the change was clear: trained, experienced GPs working in structured clinical environments can safely and effectively manage adult ADHD. The psychiatrist-only model was creating more harm through delayed treatment than any theoretical risk from broadening prescribing authority.

South Australia Follows Suit

South Australia moved quickly after Queensland's lead. In early 2026, SA Health launched its own GP ADHD training program, with the first cohort of approximately 100 trained GPs becoming active prescribers from late February 2026.

The SA model requires GPs to complete an approved training course — the Psych Scene Hub Clinical Excellence in Adult ADHD program being one of the primary accepted pathways. This course covers ADHD neurobiology, diagnostic assessment, medication management (including stimulants and non-stimulants), comorbidity management, and ongoing monitoring protocols.

The SA approach is more structured than Queensland's, with explicit training requirements and a formal registration process for prescribing GPs. Both models, however, share the core principle: expanding access through well-trained general practitioners rather than maintaining an unsustainable reliance on a small pool of specialists.

The National Picture: State-by-State

Queensland: Fully live. FRACGP GPs can assess, diagnose, and prescribe stimulants for adult ADHD within appropriate governance structures.

South Australia: Live as of February 2026. Trained cohort active. Requires approved ADHD training course completion.

ACT: Allows continuation prescribing only — GPs can maintain existing treatment plans initiated by a psychiatrist but cannot initiate new stimulant prescriptions. Lower priority for telehealth clinics due to the small population and limited scope.

NSW and Victoria: Regulatory frameworks under review. Both states have signalled intent to expand GP prescribing authority but have not yet published formal guidelines. Expected to follow QLD/SA within 12–18 months.

Western Australia and Tasmania: Not currently viable for telehealth-only ADHD models due to stricter regulatory requirements around in-person assessment and prescribing restrictions. Face-to-face components may be required.

Northern Territory: Small population and complex regulatory environment. Not a priority market for most telehealth providers but may benefit from the expanded prescribing framework over time.

The direction of travel nationally is clear. The RACGP has been advocating for expanded GP involvement in ADHD care for several years, and the successful implementation in QLD and SA is providing the evidence base that other states need to follow.

How Telehealth Transforms ADHD Access

The combination of GP prescribing rights and telehealth delivery creates something genuinely new in Australian healthcare: accessible, timely ADHD assessment and treatment for adults anywhere in the country, without the 12–24 month wait for a psychiatrist and without the need to find a local clinic that happens to offer ADHD services.

This is particularly transformative for rural and regional Australians. The Department of Health has long documented the specialist workforce shortage outside capital cities. A farmer in western Queensland or a teacher in regional South Australia now has the same access to specialist ADHD assessment as someone in Brisbane or Adelaide — all via a video consultation from their home.

Specialist telehealth clinics like ADHD GP Australia focus exclusively on adult ADHD. The GPs who consult within these clinics see ADHD patients every day — often 20–30 per week. That volume of exposure builds a depth of clinical expertise in ADHD assessment, medication titration, and comorbidity management that simply isn't possible for a generalist GP who might see one or two ADHD patients a month.

The clinic model also provides structured clinical governance that individual GPs in solo practice might struggle to establish: standardised assessment protocols, peer review, prescribing guidelines, and clinical supervision from experienced practitioners. This structure is precisely what the regulatory frameworks require, and it's what ensures consistent quality of care.

What a Telehealth ADHD Assessment Looks Like

A comprehensive adult ADHD assessment via telehealth typically involves:

Pre-consultation screening: Before the appointment, patients complete validated screening instruments including the ASRS-v1.1 screener, the Wender Utah Rating Scale (childhood symptoms), and detailed intake questionnaires covering medical history, psychiatric history, substance use, current medications, and functional impairment across work, relationships, and daily life.

Initial assessment consultation (45–60 minutes): A comprehensive clinical interview covering symptom history (childhood onset, persistence into adulthood), functional impairment across multiple domains, differential diagnosis (ruling out anxiety, depression, bipolar disorder, sleep disorders, thyroid conditions, and substance use), medical history review, cardiovascular risk assessment, and discussion of treatment options.

Physical health requirements: Patients typically need a recent blood pressure reading, heart rate, and baseline bloods (FBC, TFTs, LFTs) either from their regular GP or a local pathology provider. Some clinics accept readings from validated home blood pressure monitors. An ECG may be required for patients with cardiovascular risk factors.

Treatment initiation: If ADHD is diagnosed, the prescribing GP will discuss medication options — typically starting with a stimulant medication (methylphenidate or dexamphetamine) at a low dose with gradual titration. Non-stimulant options such as atomoxetine may be considered for patients with contraindications to stimulants or specific preference. The medication is prescribed electronically via eRx or token-based prescribing, dispensed at the patient's local pharmacy.

Follow-up schedule: Regular follow-ups are typically scheduled at 2 weeks, 4 weeks, and then monthly during titration, extending to 3-monthly once stable. These follow-ups monitor symptom response, side effects, cardiovascular parameters, and overall wellbeing. All follow-ups can be conducted via telehealth.

Medication Management in Telehealth ADHD Care

The medications used in adult ADHD treatment are well-established and extensively studied. The Therapeutic Goods Administration (TGA) regulates all ADHD medications in Australia, and the Pharmaceutical Benefits Scheme (PBS) subsidises several formulations.

First-line stimulant medications available in Australia include methylphenidate (available as Ritalin, Ritalin LA, and Concerta) and dexamphetamine (available as tablets and as the prodrug lisdexamfetamine/Vyvanse). The choice between these depends on individual response, tolerability, desired duration of action, and cost considerations.

Non-stimulant options include atomoxetine (Strattera) and guanfacine (Intuniv), which may be appropriate for patients with anxiety comorbidity, substance use history, cardiovascular concerns, or personal preference. These medications have different onset profiles — typically requiring 4–8 weeks to reach full efficacy compared to the more immediate effect of stimulants.

Telehealth delivery does not change any aspect of the clinical pharmacology or monitoring requirements. The same careful titration protocols, cardiovascular monitoring, and regular review schedules apply regardless of whether the consultation is conducted via video or in person. The Australian Health Practitioner Regulation Agency (AHPRA) holds telehealth practitioners to identical clinical standards as face-to-face practitioners.

What This Means for GPs

If you're an FRACGP with an interest in mental health, neurodiversity, or ADHD specifically, this regulatory shift creates a genuine professional opportunity. The demand is enormous, largely unmet, and growing. Adult ADHD is an area where a GP can develop real subspecialty expertise — the clinical complexity is engaging, the patient outcomes are often dramatic, and the ongoing management relationships are rewarding.

Specialist telehealth networks like Telehealth Australia Group handle the non-clinical infrastructure: patient acquisition through digital marketing, appointment scheduling, billing, clinical governance frameworks, and administrative support. GPs receive 65–70% of private billings, choose their own hours, and focus purely on the clinical work they trained for.

The learning curve is manageable. Most GPs with a solid foundation in mental health can develop clinical confidence in ADHD assessment and management within their first 20–30 patients, particularly within a structured environment that provides clinical induction, treatment protocols, and access to experienced peers.

Apply to Consult in ADHD →